The clinical significance of IDH mutations in essential thrombocythemia and primary myelofibrosis

Basit Öğe Kaydı
dc.contributor.authorYönal Hindilerden, İpek
dc.contributor.authorDağlar Aday, Aynur
dc.contributor.authorHindilerden, Fehmi
dc.contributor.authorAkadam Teker, Başak
dc.contributor.authorYılmaz, Ceylan
dc.contributor.authorNalçacı, Meliha
dc.contributor.authorYavuz, Akif Selim
dc.contributor.authorSargın, Deniz
dc.date.accessioned2020-07-08T16:37:20Z
dc.date.available2020-07-08T16:37:20Z
dc.date.issued2016
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: Limited data exist regarding impact of IDH mutations in Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs). Prognostic significance of IDH mutations was asessed in 184 Ph-negative MPN patients - 107 essential thrombocythemia (ET) and 77 primary myelofibrosis (PMF). Methods: High-resolution melting (HRM) analysis was used to detect IDH1 and IDH2 mutations. Results: PMF and ET patients showed no significant difference for prevalence of IDH mutations. Mutant IDH (IDH1 or IDH2) was documented in five of PMF (6.5%) and two of ET patients (1.9%). IDH mutations in ET patients included one IDH1 R132C and one IDH2 R140Q. Of the five IDH-mutated PMF patients, four (80%) displayed IDH1 (three IDH1 R132C and one IDH1 R132S) and one (20%) carried IDH2 (IDH2 R140Q) mutation. Sixty percent (three in five) of IDH-mutated PMF patients carried JAK2V617F with following allele burdens: 31-50%, 5-12.5% and 31-50%, respectively. Three of 77 PMF patients (3.9%) simultaneously harbored IDH and JAK2V617F mutations. IDH mutations in PMF showed a trend towards higher rate in females (100% and 52.8%, respectively). Bleeding complications were significantly higher in IDH-mutated PMF patients compared to IDH wild-type counterparts. Trend towards a lower prevalance of acetylsalicylic acid (ASA) use was present in IDH mutant PMF patients compared to wild-type counterparts (20% and 63.9%, respectively). Death rate was higher in IDH-mutated PMF patients compared to IDH wild-type PMF patients (60% and 15.3%). In univariate analysis, a significantly shorter leukemia-free survival (LFS) was observed in IDH-mutated PMF patients. Conclusions: We conclude that IDH mutations indicate a risk for leukemic transformation in PMF.
dc.identifier.citationYönal Hindilerden, İ., Dağlar Aday, A., Hindilerden, F., Akadam Teker, B., Yılmaz, C., Nalçacı, M. ... Sargın, D. (2016). The clinical significance of IDH mutations in essential thrombocythemia and primary myelofibrosis. Journal of Clinical Medicine Research, 8(1), 29-39. https://dx.doi.org/10.14740/jocmr2405w
dc.identifier.doi10.14740/jocmr2405w
dc.identifier.endpage39
dc.identifier.issue1
dc.identifier.startpage29
dc.identifier.urihttps://dx.doi.org/10.14740/jocmr2405w
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5430
dc.identifier.volume8
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElmer Press
dc.relation.ispartofJournal of Clinical Medicine Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution 3.0 United States*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectPhiladelphia-Negative Myeloproliferative Neoplasms
dc.subjectIDH1
dc.subjectIDH2
dc.titleThe clinical significance of IDH mutations in essential thrombocythemia and primary myelofibrosis
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
sargin, deniz-2015.pdf
Boyut:
1.1 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu